Bio-Techne Corp.
TECH Real Time Price USDRecent trades of TECH by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by TECH's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$10,000 Apr 15, 2024 Issue: Budget/Appropriations Agriculture
Estimated quarterly lobbying spending
TECH Revenue by Segment or Geography
New patents grants
-
Patent Title: Hybridoma clones, monoclonal antibodies to vsig-4, and methods of making and using Feb. 13, 2024
-
Patent Title: Compounds that modulate the interaction of vista and vsig3 and methods of making and using Oct. 17, 2023
-
Patent Title: Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy May. 16, 2023
-
Patent Title: Il-37 fusion protein and methods of making and using same Dec. 13, 2022
-
Patent Title: Methods for non-invasive profiling of stem cell differentiation Aug. 31, 2021
-
Patent Title: Wnt/sfrp complexes, wnt-containing compositions, wnt-expressing cells, and methods of making, purifying, and using same Jun. 29, 2021
-
Patent Title: Methods and kits for assaying endoglycosidase activity Jan. 12, 2021
-
Patent Title: Hybridoma clones, monoclonal antibodies to vsig-4, and methods of making and using Aug. 25, 2020
-
Patent Title: Dual chamber storage device May. 05, 2020
-
Patent Title: Methods and kits for detection of o-glcnac and n-glcnac modification of peptides and proteins Aug. 09, 2016
-
Patent Title: Phosphatase coupled glycosyltransferase assay Aug. 09, 2016
Federal grants, loans, and purchases
- $24,462 2024-09-24 00:00:00 Agency: Department of Health and Human Services
- $24,462 2024-09-24 00:00:00 Agency: Department of Health and Human Services
- $20,328 2024-08-07 00:00:00 Agency: Department of Health and Human Services
- $12,758 2024-08-02 00:00:00 Agency: Department of Health and Human Services
- $10,500 2024-05-06 00:00:00 Agency: Department of Veterans Affairs
- $24,986 2023-09-22 00:00:00 Agency: Department of Health and Human Services
- $17,611 2023-08-28 00:00:00 Agency: Department of Health and Human Services
- $19,383 2023-08-16 00:00:00 Agency: Department of Health and Human Services
- $11,685 2023-07-18 00:00:00 Agency: Department of Health and Human Services
- $14,400 2023-07-18 00:00:00 Agency: Department of Health and Human Services
- $24,395 2023-06-15 00:00:00 Agency: Department of Health and Human Services
- $19,972 2023-06-08 00:00:00 Agency: Department of Health and Human Services
- $23,900 2023-05-09 00:00:00 Agency: Department of Health and Human Services
Estimated quarterly amount awarded from public contracts
Recent insights relating to TECH
Recent picks made for TECH stock on CNBC
ETFs with the largest estimated holdings in TECH
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $TECH stock a Buy, Sell, or Hold?
- What is the price target for $TECH stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $TECH stock?
- Who owns the most shares of $TECH stock?
- What funds own $TECH stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view TECH Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.